Tscan Therapeutics, Inc. (TCRX) Stock Price & Analysis
Tscan Therapeutics, Inc. (TCRX) fell 11.93% to USD 0.34 as of September 8, 2026 at 22:16 UTC, according to Nexqual real-time market data.
TCRX last closed at USD 0.34; the session ranged USD 0.33–0.38 on volume of 1,532,183 shares. Market capitalization is —, with a 52-week range of USD 0.33–2.57 (NGM). Source: Nexqual, September 8, 2026 at 22:16 UTC.
Key Statistics (as of September 8, 2026 at 22:16 UTC)
| Price | USD 0.34 |
|---|---|
| Change | ▼ 11.93% (down) |
| Previous Close | USD 0.34 |
| Open | USD 0.34 |
| Day Range | USD 0.33 – 0.38 |
| 52-Week Range | USD 0.33 – 2.57 |
| Volume | 1,532,183 shares |
| Market Cap | — |
| Exchange | NGM |
Technical Analysis (TCRX)
Nexqual's technical model rates TCRX "SELL" based on 3 bullish and 5 bearish signals across 127 daily candles, as of September 8, 2026 at 22:16 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 16.39 (oversold) |
| vs SMA50 | Below (USD 0.82) |
| MACD | -0.11 (negative) |
From Tscan Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-04)
Key Strengths & Strategy (as disclosed to the SEC)
- Our current proprietary pipeline is summarized in the figure below.         In addition to our proprietary pipeline programs noted above, we have also entered into collaborations with strategic partners for applications of our platform technologies.
- The term of the royalty agreement continues until expiration of the last applicable royalty term.   Manufacturing   We have built in-house cell therapy manufacturing capabilities as one of the key components of our platform.
- To provide an operationally flexible and cost-effective approach for our heme program, we have developed a manufacturing platform to genetically engineer T cells using a transposon/transposase system.
- Our non-viral vector delivery system allows us to include additional T cell enhancements in our product candidates.
Partnerships
- License and Collaboration Agreements Collaboration Agreement with Amgen   On May 8, 2023, we entered into a Research Collaboration and License Agreement with Amgen Inc. (Amgen), or the Amgen Agreement, to identify antigens recognized by T cells in patients with Crohn's disease utilizing our proprietary target discovery platform.
- To date, we have a research collaboration and license agreement with Amgen to identify the antigens recognized by T cells in patients with Crohn's disease.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INAB | IN8bio, Inc. | USD 1.14 | ▼ 1.72% |
| ABOS | Acumen Pharmaceuticals, Inc. | USD 3.16 | ▲ 2.27% |
| IPSC | Century Therapeutics, Inc. | USD 2.07 | ▼ 0.96% |
| SERA | Sera Prognostics, Inc. | USD 2.01 | ▲ 1.52% |
| ERAS | Erasca, Inc. | USD 16.28 | ▲ 0.12% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 22:16 UTC. This page is informational and not investment advice.